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Objective: The prognosis for colon and rectal cancer has improved in Denmark over the past 
decades but is still poor compared with that in our neighboring countries. We conducted this 
population-based study to monitor recent trends in colon and rectal cancer survival in the central 
and northern regions of Denmark.
Material and methods: Using the Danish National Registry of Patients, we identified 
9412 patients with an incident diagnosis of colon cancer and 5685 patients diagnosed with 
rectal cancer between 1998 and 2009. We determined survival, and used Cox proportional haz-
ard regression analysis to compare mortality over time, adjusting for age and gender. Among 
surgically treated patients, we computed 30-day mortality and corresponding mortality rate 
ratios (MRRs).
Results: The annual numbers of colon and rectal cancer increased from 1998 through 2009. For 
colon cancer, 1-year survival improved from 65% to 70%, and 5-year survival improved from 
37% to 43%. For rectal cancer, 1-year survival improved from 73% to 78%, and 5-year survival 
improved from 39% to 47%. Men aged 80+ showed most pronounced improvements. The 1- and 
5-year adjusted MRRs decreased: for colon cancer 0.83 (95%   confidence interval CI: 0.76–0.92) 
and 0.84 (95% CI: 0.78–0.90) respectively; for rectal cancer 0.79 (95% CI: 0.68–0.91) and 0.81 
(95% CI: 0.73–0.89) respectively. The 30-day postoperative mortality after resection also declined 
over the study period. Compared with 1998–2000 the 30-day MRRs in 2007–2009 were 0.68 
(95% CI: 0.53–0.87) for colon cancer and 0.59 (95% CI: 0.37–0.96) for rectal cancer.
Conclusion: The survival after colon and rectal cancer has improved in central and northern 
  Denmark during the 1998–2009 period, as well as the 30-day postoperative mortality.
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Introduction
Colorectal cancer (CRC) is one of the most common malignancies in industrialized 
countries and one of the most common causes of cancer-related death.1,2 In Denmark, 
approximately 4200 new cases of CRC are diagnosed each year,3 with a 5-year survival 
of only 43%–49%.4,5 Danish CRC survival is lower than in our neighboring counterparts 
and countries with similar health systems,6,7 probably due to higher mortality in the 
first year after diagnosis.5,6,8
Similar to CRC, Denmark has lower survival for many other cancer sites.5,6,9 
Aiming to improve cancer control, the first National Cancer Plan was established 
in 2000.10 The main topics were expansion of the diagnostic and nonsurgical treat-
ment capacity, as well as establishment of multidisciplinary cancer groups and 
implementation of clinical databases in order to monitor quality of cancer treatment. Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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In 2005, the second National Cancer Plan was launched11 and 
concerned the reduction of diagnostic and treatment delays 
by organizing the cancer pathways, as well as strengthening 
the cancer surgery by centralization and in-service training. 
Although these different initiatives may have the potential 
of improving survival in CRC patients, no updated data on 
survival exist. We therefore conducted the present study to 
monitor survival and mortality in colon and rectal cancer 
patients using existing data from the central and northern 
Danish regions.
Material and methods
We conducted this study in the central and northern Denmark 
regions with a combined population of 1.8 million persons. 
The National Health Service provides tax-supported health 
care for all inhabitants of Denmark, guaranteeing free access 
to general practitioners and hospitals.
Identification of CRC patients
Through the Danish National Registry of Patients (DNRP), 
we identified all patients who had a first-time hospitaliza-
tion with colon or rectal cancer between January 1, 1998 
and December 31, 2009. The DNPR includes data on per-
sonal identification number, hospital, department,   surgical 
and diagnostic procedures, and discharge diagnoses, as 
defined by the International Classification of Diseases 
10th edition (ICD-10) by 1993.12 The ICD-10 codes used 
to identify colonic cancer were C18–19 and rectal cancer 
C20–21.
Survival
Since 1968, the Central Office of Civil Registration has 
assigned a unique 10-digit civil registration number to all 
Danish citizens,13 which enables unambiguous data linkage 
between Danish registries. The Civil Registration System 
also contains information on vital status, date of death, and 
residence.
Statistical analysis
We followed each patient from the date of colon or   rectal 
cancer diagnosis until emigration, death, or June 25th 
2010, whichever came first. To visualize crude survival we 
constructed Kaplan–Meier curves stratified according to 
periods of colon or rectal cancer diagnosis (1998–2000, 
2001–2003, 2004–2006, and 2007–2009), estimating 1- and 
5-year survival. In the latter periods we predicted 5-year 
survival using a hybrid analysis in which we included the 
actual survival for as long as possible and then estimated 
the conditional probability of surviving thereafter based 
on the corresponding survival experience of patients in the 
previous period (ie, using a period analysis technique).14 
To compare mortality over time we used Cox proportional 
hazards regression analysis with 1998–2000 as a reference 
to estimate 1- and 5-year mortality rate ratios (MRRs) and 
the corresponding 95% confidence intervals (CIs) adjusting 
for age groups (15–64 years, 65–79 years, 80+ years) 
and gender. Additionally, analyses were stratified on age 
and gender. For the patients who underwent surgery, we 
likewise computed 30-day mortality rates for the four time 
periods. Surgery was defined as resection or first operative 
procedure, although the latter included resections if these 
were initially performed (see Appendix 1 for codes). First 
operative procedure also included defunctional procedures 
and/or definitive palliative procedures. Thus, a patient 
could enter both surgery groups in the case of an initial 
defunctional procedure and a resection hereafter. We used 
Cox proportional hazards regression analysis and estimated 
30-day MRRs with 1998–2000 as a reference, adjusting for 
age and gender. Analyses were performed using SAS version 
9.2 (SAS Institute Inc, Cary, NC).
Results
Colon cancer
A total of 9412 patients were diagnosed with colon cancer in 
the 1998–2009 period. The number of colon cancer patients 
increased from a total of 2097 in 1998–2000 to 2763 in 
2007–2009 (Table 1), most pronounced among men (Table 2). 
At the same time median age at diagnosis declined from 73 
years to 72 years. One-year overall survival improved from 
65% to 70% over the study period, corresponding to an 
adjusted MRR of 0.83 (95% CI: 0.76–0.92) in 2007–2009 
using 1998–2000 as a   reference (Figure 1 and Table 1). 
  Accordingly, the 5-year overall   survival improved from 37% 
to predicted 43%, corresponding to a 5-year adjusted MRR 
of 0.84 (95% CI: 0.78–0.90) in 2007–2009 compared with 
1998–2000. In general, in both genders and in all age groups 
the   survival improved. Five-year survival improved particu-
larly in men aged 15–64 and 80+ as well as in women aged 
80+ (Table 2).
The 30-day postoperative mortality decreased during the 
study period; after resection from 9% in 1998–2000 to 7% in 
2007–2009 (adjusted MRR 0.68 (95% CI: 0.53–0.87)) and 
after the first operative procedure from 11% to 8% (adjusted 
MRR 0.71 (95% CI: 0.57–0.88)) (Table 3).Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
29
Survival of patients with colon and rectal cancer
rectal cancer
A total of 5685 patients were diagnosed with rectal cancer in 
the 1998–2009 period. The number of rectal cancer patients 
increased during the four time intervals from a total of 1336 to 
1554 (Table 1), most pronounced among the youngest men and 
women (Table 2). At the same time, median age at diagnosis 
declined from 71 years to 69 years. The 1-year overall survival 
improved from 73% to 78%, corresponding to an adjusted MRR 
of 0.79 (95% CI: 0.68–0.91) in 2007–2009 using 1998–2000 
as a reference (Figure 1 and Table 1). Accordingly, the 5-year 
survival improved from 39% 1998–2000 to the predicted 47% 
in 2007–2009, corresponding to an adjusted MRR of 0.81 
(95% CI: 0.73–0.89). In general, improvements in survival 
were present in all age groups in both genders apart from 
1-year survival in women aged 80+. Men aged 80+ showed 
remarkable improvements in 1- and 5-year survival, whereas 
5-year survival also improved notably in both genders aged 
65–79 (Table 4).
As for colon cancer patients, the 30-day postoperative 
mortality decreased for rectal cancer patients over the study 
period. After resection, 30-day mortality decreased from 5% 
in 1998–2000 to 3% in 2007–2009 (adjusted MRR of 0.59 
(95% CI 0.37–0.96)), and after the first operative procedure 
the 30-day mortality decreased from 7% to 4% (adjusted 
MRR of 0.61 (95% CI 0.41–0.89)) (Table 3).
Discussion
In this large population-based study we found an improved 
survival in both colon and rectal cancer patients. Accordingly, 
the 30-day postoperative mortality also decreased for both 
cancer locations.
The main strength of this study is the population-based 
design with a large sample size covering about 30% of the 
Danish population and a complete hospital history. We had 
complete follow-up on all patients ensured by the Civil 
Registration System. These features minimize the risk of 
selection bias. We used the DNRP since it is continuously 
updated and has been demonstrated to be complete and 
valid.15,16 We consider overall survival as a valid outcome 
measurement in this study of prognostic changes over time, 
rather than disease-specific survival, which may be affected 
by bias in classifying the cause of death. Such bias may be 
differential according to time period.17
Our study also had limitations. First, we had no data on 
cancer stage and thus were unable to evaluate whether the 
improvements in survival stemmed from better treatment or 
Table 1 One- and 5-year survival and Mrrs (and 95% Cis) after colon and rectal cancer diagnosis according to the time periods
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
Colon cancer
  number of cancer patients 2097 2160 2392 2763
  Median age (years) 73 73 73 72
  1-year
  Survival 65% (63%–67%) 67% (64%–68%) 69% (68%–71%) 70% (68%–71%)
  Mrr 1 (reference) 0.96 (0.87–1.06) 0.85 (0.77–0.94) 0.84 (0.76–0.93)
  Mrra 1 (reference) 0.97 (0.88–1.08) 0.85 (0.77–0.94) 0.83 (0.76–0.92)
  5-year
  Survival 37% (35%–39%) 40% (38%–42%) 43% (41%–45%)b 43% (41%–45%)b
  Mrr 1 (reference) 0.93 (0.86–1.00) 0.85 (0.79–0.92)b 0.84 (0.78–0.91)b
  Mrra 1 (reference) 0.93 (0.86–1.00) 0.85 (0.78–0.91)b 0.84 (0.78–0.90)b
Rectal cancer 
  number of cancer patients 1336 1396 1399 1554
  Median age (years) 71 70 69 69
  1-year
  Survival 73% (70%–75%) 74% (72%–76%) 76% (73%–78%) 78% (76%–80%)
  Mrr 1 (reference) 0.94 (0.82–1.09) 0.89 (0.77–1.03) 0.77 (0.66–0.89)
  Mrra 1 (reference) 0.97 (0.84–1.13) 0.91 (0.78–1.05) 0.79 (0.68–0.91)
  5-year
  Survival 39% (36%–42%) 43% (40%–46%) 46% (43%–48%)b 47% (45%–50%)b
  Mrr 1 (reference) 0.90 (0.82–1.00) 0.84 (0.77–0.93)b 0.79 (0.72–0.88)b
  Mrra 1 (reference) 0.92 (0.83–1.02) 0.85 (0.77–0.94)b 0.81 (0.73–0.89)b
Notes: aadjusted for age and gender; bpredicted values.
Abbreviations: CI, confidence interval; MRR, mortality rate ratio.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Table 2 One- and 5-year survival after colon cancer diagnosis according to age at diagnosis and time periods
Age (years) Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
Men
15–64 number of cancer patients 282 323 346 401
1-year survival 74% (69%–79%) 77% (72%–81%) 80% (75%–84%) 80% (76%–84%)
5-year survival 45% (39%–50%) 45% (40%–50%) 54% (49%–59%)a 56% (50%–61%)a
65–79 number of cancer patients 484 502 562 691
1-year survival 66% (61%–70%) 64% (60%–68%) 70% (66%–73%) 70% (66%–73%)
5-year survival 36% (32%–40%) 39% (35%–43%) 42% (38%–46%)a 41% (37%–45%)a
80+ number of cancer patients 208 228 247 310
1-year survival 49% (42%–56%) 54% (47%–60%) 59% (53%–65%) 57% (51%–63%)
5-year survival 17% (13%–23%) 27% (21%–33%) 24% (19%–29%)a 22% (17%–27%)a
Women
15–64 number of cancer patients 294 314 300 395
1-year survival 76% (71%–81%) 82% (77%–85%) 80% (75%–84%) 78% (73%–82%)
5-year survival 48% (42%–53%) 53% (48%–59%) 57% (51%–63%)a 54% (49%–59%)a
65–79 number of cancer patients 503 489 574 570
1-year survival 68% (63%–71%) 68% (64%–72%) 74% (70%–77%) 73% (69%–76%)
  5-year survival 43% (38%–47%) 43% (38%–47%) 49% (45%–53%)a 48% (44%–52%)a
80+ number of cancer patients 326 304 363 396
1-year survival 52% (46%–57%) 51% (46%–57%) 50% (45%–55%) 55% (50%–60%)
5-year survival 25% (21%–30%) 29% (24%–34%) 27% (22%–31%)a 31% (26%–36%)a
Note: apredicted values.
Figure 1 Survival curves for patients with a first-time diagnosis of colon and rectal cancer.
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Table 3 Thirty-day mortality and 30-day MRRs (and 95% CIs) after resection or first surgical procedure in colon and rectal cancer 
patients
Year of surgery
1998–2000 2001–2003 2004–2006 2007–2009
Colon cancer
  Resection
  number of cancer patients 1471 1507 1674 1690
  Median age (years) 73 72 72 72
  30-day mortality 9% (8%–11%) 10% (9%–12%) 7% (6%–8%) 7% (5%–8%)
  30-day Mrr 1 (reference) 1.12 (0.89–1.41) 0.71 (0.55–0.91) 0.69 (0.53–0.88)
  30-day Mrra 1 (reference) 1.14 (0.91–1.44) 0.71 (0.55–0.91) 0.68 (0.53–0.87)
  First surgical procedure
  number of cancer patients 1622 1615 1803 1880
  Median age (years) 73 73 73 72
  30-day mortality 11% (9%–12%) 12% (10%–13%) 8% (7%–10%) 8% (7%–9%)
  30-day Mrr 1 (reference) 1.09 (0.89–1.34) 0.74 (0.60–0.92) 0.71 (0.57–0.88)
  30-day Mrra 1 (reference) 1.12 (0.91–1.38) 0.75 (0.60–0.93) 0.71 (0.57–0.88)
Rectal cancer
  Resection
  number of cancer patients 865 852 773 890
  Median age (years) 70 69 68 68
  30-day mortality 5% (4%–7%) 5% (4%–7%) 5% (4%–7%) 3% (2%–4%)
  30-day Mrr 1 (reference) 0.95 (0.63–1.44) 1.00 (0.66–1.53) 0.54 (0.34–0.88)
  30-day Mrra 1 (reference) 1.06 (0.70–1.61) 1.04 (0.68–1.58) 0.59 (0.37–0.96)
  First surgical procedure
  number of cancer patients 1025 1019 937 1087
  Median age (years) 71 70 69 69
  30-day mortality 7% (5%–8%) 6% (5%–8%) 7% (5%–9%) 4% (3%–5%)
  30-day Mrr 1 (reference) 0.95 (0.67–1.33) 1.02 (0.73–1.43) 0.56 (0.38–0.83)
  30-day Mrra 1 (reference) 1.02 (0.73–1.43) 1.05 (0.75–1.48) 0.61 (0.41–0.89)
Note: aadjusted for age and gender.
Abbreviations: CI, confidence interval; MRR, mortality rate ratio.
Table 4 One- and 5-year survival after rectal cancer diagnosis according to age at diagnosis and time periods
Age (years) Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
Men
15–64 number of cancer patients 248 301 315 338
1-year survival 84% (79%–88%) 82% (78%–86%) 83% (79%–87%) 89% (85%–92%)
5-year survival 53% (47%–59%) 53% (47%–58%) 54% (48%–59%)a 58% (52%–63%)a
65–79 number of cancer patients 343 367 383 427
1-year survival 72% (67%–77%) 71% (66%–75%) 72% (68%–77%) 78% (74%–82%)
5-year survival 37% (32%–42%) 40% (35%–45%) 42% (37%–47%)a 45% (40%–50%)a
80+ number of cancer patients 133 117 128 146
1-year survival 48% (39%–56%) 60% (50%–68%) 55% (46%–64%) 63% (54%–70%)
5-year survival 14% (8%–20%) 24% (17%–32%) 22% (16%–30%)a 23% (16%–31%)a
Women
15–64 number of cancer patients 191 215 210 252
1-year survival 82% (76%–87%) 89% (84%–92%) 91% (87%–95%) 87% (83%–91%)
5-year survival 54% (46%–61%) 59% (52%–65%) 66% (59%–72%)a 63% (56%–68%)a
65–79 number of cancer patients 292 267 229 256
1-year survival 76% (71%–81%) 73% (67%–78%) 75% (69%–80%) 77% (71%–82%)
5-year survival 40% (35%–46%) 43% (37%–49%) 48% (42%–54%)a 49% (43%–55%)a
80+ number of cancer patients 129 129 134 135
1-year survival 57% (48%–65%) 57% (48%–65%) 61% (52%–69%) 55% (46%–63%)
5-year survival 19% (13%–27%) 20% (14%–27%) 25% (18%–32%)a 22% (15%–29%)a
Note: apredicted values.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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diagnosis at an earlier stage. However, data on previous stage 
distribution in CRC reveal no substantial change during the 
2001–2008 period,18 thus speaking against major changes 
towards earlier diagnosis.19 Length time and lead time biases 
are therefore unlikely.20 Second, life expectancy has increased 
in the general population, particularly for men.21 Therefore, 
our findings of improved survival being most pronounced 
among men aged 80+ may partly be attributable to a reduced 
mortality in general. Still, Coleman et al found that the 1-year 
relative survival of colorectal cancer in Denmark (ie, the ratio 
between observed survival and expected survival based on 
the background mortality) improved from 71.7% to 77.7% in 
the period 1995–2007.6 This finding indicates that increased 
life expectancy in general is not solely responsible for the 
improved survival reported in our study.
A number of initiatives have been launched during the 
last decades to improve CRC prognosis. In 1998 the Danish 
  Colorectal Cancer Group first published national clinical 
guidelines for diagnosis and treatment of CRC.22 Further-
more, National Cancer Plans were introduced in 2000 
and 2005 aiming also to improve health care organization 
and avoiding delay in cancer diagnostics and treatment. 
According to this, the surgical treatment of CRC patients 
has generally been centralized. However, evidence of the 
impact of high hospital procedure volume and high surgeon 
case volume on CRC prognosis is inconsistent, although 
some reviews have shown benefits.23–25 Furthermore, in 
rectal cancer treatment, multidisciplinary teams comprising 
radiologists, pathologists, surgeons, and oncologists have 
been established.
In addition to these initiatives, refinements over time of 
diagnostic procedures and techniques, such as endoscopy, 
computerized tomography, magnetic resonance, ultrasonic 
scanning, and position emission tomography may also have 
played a role in improving CRC diagnosis by facilitating earlier 
and more accurate diagnosis. However, the similar stage distri-
bution in CRC in Denmark in the period 2001–200818 indicates 
that these advances may only have played a minor role.
The surgical treatment of CRC has also developed 
over the study period, in at least three ways. First, total 
mesorectal excision technique was adapted in Denmark 
in 1996 in rectal cancer surgery. Improved survival by 
reduced local recurrence rate has been observed after 
implementation of this technique.26–28 Second, treatment of 
cancer-related acute colonic obstruction by self-expanding 
metallic stents has been introduced.29 This technique has 
the potential of converting emergent procedures into 
planned procedures,30 which are associated with better 
survival.31–33 Third,   laparoscopic surgery is now widely 
implemented.29 Although randomized clinical trials on 
colon cancer tend to show improved short-term mortality 
by laparoscopic procedures compared with open surgery, 
long-term mortality does not differ significantly, and 
for rectal cancer, evidence on mortality improvements 
by laparoscopic surgery is less clear.34,35 In addition to 
the   potential improvements in surgical treatment, bet-
ter perioperative care may also have contributed to the 
observed survival improvements. Furthermore, during the 
study period, an oxaliplatin-containing adjuvant chemo-
therapy regimen has been introduced in the treatment of 
colonic cancer36–38 as well as biological monoclonal anti-
bodies to selected patients with metastatic CRC.39,40 For 
rectal cancer, preoperative radiotherapy with or without 
concomitant chemotherapy has been introduced. However, 
randomized clinical trials show lower local recurrence rate, 
but no effect on survival.41,42
The results from our study extend those from previous 
population-based studies based on data from the DNRP43 and 
the Danish Cancer Registry.6,7,44 Compared with our Nordic 
counterparts and countries with similar health systems, CRC 
survival in Denmark is still inferior despite the reported 
improvements.6,7 This underlines the need of further initia-
tives, although we may await effects of the National Cancer 
Plans already implemented.
Conclusion
In conclusion, survival after colon and rectal cancer has 
improved in central and northern Denmark during the 1998–
2009 period. Accordingly, 30-day postoperative mortality 
after colon and rectal cancer has also improved.
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Appendix 1
Surgery codes for colon cancer resections were JFB20-97 
and JFHxx, and for colon cancer first operative procedure, 
JFA68, JFA83–84, JFA96–97, JFCxx, JFF10–13, JFF20–31, 
JFWxx.   Similarly, surgery codes for rectal resections were 
JGB00–50 and JGB96–97, and for rectal, first surgical 
procedures were JGA32–52, JGA73–96, JGA98, JGWxx, 
JFF10–13, JFF20–31, and JFA68.